Photocure ASA (PHO) Earnings Call Transcripts

Photocure ASA's Latest Earnings Call - June 5, 2026

In the Q1 2026 earnings call, Photocure ASA announced a significant acquisition of Vesica Health for approximately $30.5 million, aimed at enhancing its bladder cancer diagnostic capabilities. The company reported a revenue growth of 11% for fiscal year 2025 and an adjusted EBITDA margin of 11% for Q1 2026, with guidance for product revenue growth maintained at 7% to 11% for 2026. Management expressed optimism about the strategic fit of Vesica's AssureMDx product, which is expected to tap into a $6 billion hematuria valuation market, potentially driving revenue growth above 25% annually from 2026 through 2030.

Reported metrics

Guidance from management

Management maintained its revenue growth guidance for 2026 at 7% to 11% and expects initial AssureMDx revenues in 2027, with positive EBITDA contribution by 2030.

What management said

Yes. Thank you, Dan. Now when comparing AssureMDx against competing technologies, we believe the product is exceptionally differentiated. It combines 2 independent biological mechanisms. DNA methylation and somatic mutation analysis, whereas many competitors rely on a single modality or even suboptimal analytes. The supporting evidence space is also remarkably robust, including multiple prospective validation studies...

I'll start and maybe Chris might want to jump in here, too. We continue to invest in generating the clinical evidence and the health economics to support CMS coverage for AssureMDx. Our belief in other diagnostic companies have demonstrated this is that a robust clinical evidence and health economics data ultimately will drive reimbursement covers. That's why we'll continue to invest in retimed controlled trials like...

What analysts pressed on

Analysts expressed concerns regarding the timeline for Medicare reimbursement and the potential risks associated with the milestones tied to the Vesica acquisition. Questions were raised about how AssureMDx will generate revenues before full reimbursement is achieved.

Main topics on the call

• Acquisition of Vesica Health — Photocure announced the acquisition of Vesica Health for $30.5 million, which includes both cash and equity. CEO Daniel Schneider stated, "We believe the transaction was completed at an attractive valuation and at the ri...
• Revenue Growth and EBITDA Margins — Photocure reported an 11% revenue growth for fiscal year 2025 and an adjusted EBITDA margin of 11% for Q1 2026. Management maintained guidance for product revenue growth of 7% to 11% for 2026, signaling confidence in the...
• Market Opportunity for AssureMDx — The acquisition of AssureMDx allows Photocure to access a larger $6 billion hematuria market. Schneider noted, "We now participate across a broader portion of the bladder cancer continuum," emphasizing the strategic impo...
• CMS Reimbursement Timeline — Management indicated that Medicare reimbursement for AssureMDx could come as early as mid-2027, which is crucial for revenue generation. Schneider mentioned, "There has been a recent unexpected and encouraging positive n...

Read the full Photocure ASA transcript (June 5, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 28 Photocure ASA earnings call transcripts on record, spanning February 27, 2020 to July 29, 2026. Based on this history, Photocure ASA reports quarterly. The most recent call on file is dated July 29, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

PHO

Exchange

OB

Country

NO

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

28

First call

February 27, 2020

Most recent

July 29, 2026

Reporting cadence

quarterly